Clinical medicine profile
Montelukast / Levocetirizine
Therapeutic agent (verify pharmacological class)
- Route
- See product SmPC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- [Montelukast] Hypersensitivity to the active substance or excipients.
- Additional absolute contraindications are indication- and product-specific — consult SmPC. [Levocetirizine] [Levocetirizine] Hypersensitivity to the active substance or excipients.
- Additional absolute contraindications are indication- and product-specific — consult SmPC. [Montelukast] Hypersensitivity to the active substance or excipients.
- Additional absolute contraindications are indication- and product-specific — consult SmPC.
Precautions
- [From component Montelukast] Monitoring of patient when systemic corticosteroid reduction is considered.
- Combination therapy with bronchodilator.
- Exercise-induced asthma.
- Pregnancy and lactation
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.
Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Use, effects & interactions
Indications
- Therapeutic use is agent- and indication-specific within the class (Therapeutic agent (verify pharmacological class)).
- Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
- Allergic rhinitis
Adverse effects
- [From component Montelukast] Dream abnormalities, hallucinations, palpitations, drowsiness, irritability, restlessness, insomnia, increased sweating, headache
- nausea, vomiting, dyspepsia, diarrhea, abdominal pain
- myalgia including muscle cramps
- increased bleeding tendency, bruising edema
- tremor, dry mouth, vertigo, arthralgia.
Drug interactions
Open multi-drug checker ↗- Fixed-dose/multi-ingredient product.
- Clinical details partially inherited from component monographs: Montelukast, Levocetirizine.
- Confirm combination SmPC for exact dosing.
Mechanism & disposition
Combination product.
Read complete mechanism
Combination product. Component mechanism (Montelukast): Inhibits airway CysLT receptors. The cysteinyl leukotrienes [LTC4, LTD4 and LTE4] are products of arachidonic acid metabolism and are released from various cells, includ-ing mast cells and eosinophils. These eicosanoids bind to cysteinyl leukotriene [CysLT] receptors. The CysLT type-1 [CysLT1] receptor is found in the human airway including airway smooth muscle cells and airway macrophages and on other pro-inflammatory cells including eosinophils and certain myeloid stem cells. CysLTs contribute to the pathophysiology of asthma and allergic rhinitis].
Product-specific
Product-specific
See product SmPC
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
[Montelukast] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist. [Levocetirizine] [Levocetirizine] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist. [Montelukast] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
[Montelukast] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data. [Levocetirizine] [Levocetirizine] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data. [Montelukast] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| MONTALLERG TABS 20*S | Not recorded | — | KES 953.72Daima Chemist price-list reference ↗ Source date not recorded · verify current price |
| MONTA PLUS TABS 10*S | Not recorded | — | UnavailableDaima Chemist price-list reference |
| Montecor Plus | Signature | mg / 10mg 30's | Unavailable |
| MONTECOR PLUS TABLETS 10*S | Not recorded | — | KES 335.40Daima Chemist price-list reference ↗ Source date not recorded · verify current price |
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.